Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Sophie GlattPeter C TaylorIain B McInnesLarissa Valor-MéndezRobert LandewéDominique BaetenLucian IonescuFoteini StrimenopoulouMark I L WatlingStevan ShawPublished in: Annals of the rheumatic diseases (2019)
PoC was confirmed based on the rapid decrease in disease activity achieved with 12 weeks of CZP plus bimekizumab. No unexpected or new safety signals were identified when neutralising IL-17A and IL-17F in patients with RA concomitantly treated with CZP, but the rate of TEAEs was higher with dual inhibition.